r 396 has been researched along with cyclo(gln-trp-phe-gly-leu-met) in 1 studies
| Studies (r 396) | Trials (r 396) | Recent Studies (post-2010) (r 396) | Studies (cyclo(gln-trp-phe-gly-leu-met)) | Trials (cyclo(gln-trp-phe-gly-leu-met)) | Recent Studies (post-2010) (cyclo(gln-trp-phe-gly-leu-met)) |
|---|---|---|---|---|---|
| 7 | 0 | 0 | 27 | 0 | 0 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Maggi, CA; Quartara, L; Rovero, P | 1 |
1 review(s) available for r 396 and cyclo(gln-trp-phe-gly-leu-met)
| Article | Year |
|---|---|
Peptide-based tachykinin NK2 receptor antagonists.
Topics: Animals; Dipeptides; Humans; Neurokinin A; Neurokinin B; Oligopeptides; Peptide Fragments; Peptides; Peptides, Cyclic; Receptors, Neurokinin-2; Receptors, Tachykinin; Substance P | 1995 |